Home > Insider Trading > Filing (0001739614-23-000006)

Filing Details

Accession Number:: 0001739614-23-000006
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-01-04 17:53:36
Reporting Period:: 2023-01-03

Accepted Time:: 2023-01-04 17:53:36
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1739614	Inhibrx Inc.	INBX	Biological Products, (No Disgnostic Substances) (2836)	824257312

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1766433	P. Brendan Eckelman	C/O Inhibrx, Inc. 11025 North Torrey Pines Road, Suite 200 La Jolla CA 92037	Chief Scientific Officer	No	Yes	No	No
1821294	Eckelman Living Trust Dated February 5, 2014	C/O Inhibrx, Inc. 11025 North Torrey Pines Road, Suite 200 La Jolla CA 92037		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-01-03	22,213	$23.41	2,133,340	No	4	S	Indirect	By the Eckelman Living Trust dated February 5, 2014
Common Stock	Disposition	2023-01-03	8,598	$24.36	2,124,742	No	4	S	Indirect	By the Eckelman Living Trust dated February 5, 2014
Common Stock	Disposition	2023-01-03	2,084	$25.09	2,122,658	No	4	S	Indirect	By the Eckelman Living Trust dated February 5, 2014
Common Stock	Disposition	2023-01-04	4,102	$23.11	2,118,556	No	4	S	Indirect	By the Eckelman Living Trust dated February 5, 2014
Common Stock	Disposition	2023-01-04	3,003	$23.99	2,115,553	No	4	S	Indirect	By the Eckelman Living Trust dated February 5, 2014

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By the Eckelman Living Trust dated February 5, 2014
No	4	S	Indirect	By the Eckelman Living Trust dated February 5, 2014
No	4	S	Indirect	By the Eckelman Living Trust dated February 5, 2014
No	4	S	Indirect	By the Eckelman Living Trust dated February 5, 2014
No	4	S	Indirect	By the Eckelman Living Trust dated February 5, 2014

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2023-01-03	40,000	$0.00	40,000	$23.30

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
40,000		2033-01-03	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	160,000	Indirect	By trust
Common Stock	160,000	Indirect	By trust

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Eckelman Living Trust dated February 5, 2014.
The shares were sold in multiple transactions at prices ranging from $23.01 to $24.00, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
These securities are directly owned by the Eckelman Living Trust dated February 5, 2014. Brendan P. Eckelman is the trustee of the Eckelman Living Trust dated February 5, 2014 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Eckelman Living Trust dated February 5, 2014.
The shares were sold in multiple transactions at prices ranging from $24.01 to $24.99, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
The shares were sold in multiple transactions at prices ranging from $25.02 to $25.48, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
The shares were sold in multiple transactions at prices ranging from $22.60 to $23.56, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
The shares were sold in multiple transactions at prices ranging from $23.61 to $24.41, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor son. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust.
These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor daughter. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust.
Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on January 3, 2024, with the balance to vest and become exercisable in equal successive monthly installments forthirty-six (36) months thereafter.